PURPOSE: Bladder pain is a debilitating symptom of many urological conditions. There is no generally effective treatment. Abnormal urothelial turnover is common to multiple disease states but the specific components of urothelial injury and the resulting molecular signals that lead to bladder pain are unknown. We examined mouse models of bladder injury induced by uropathogenic Escherichia coli, protamine sulfate (Sigma®) and bacterial lipopolysaccharide to identify cellular and molecular correlates underlying pain sensitization in response to the stimuli. MATERIALS AND METHODS: C57BL/6 female mice (Jackson Laboratory, Bar Harbor, Maine) were given intravesicular protamine sulfate, lipopolysaccharide or uropathogenic E. coli. The impact of each on nociception was determined by measuring the evoked visceromotor response to bladder distention 24 hours after inoculation. Levels of pyuria and tissue inflammation were examined by urinary cytology and tissue histology. Quantitative polymerase chain reaction and gene expression analysis were used to identify injury profiles associated with nociception. RESULTS: Protamine sulfate treatment was significantly analgesic upon bladder distention. Protamine treated bladders did not show pyuria or extensive tissue damage. Protamine injury was associated with a global decrease in the expression of inflammation associated genes. In contrast, uropathogenic E. coli injury significantly increased the nociceptive response to bladder distention. Lipopolysaccharide treatment did not affect nociception. Finally, injury induced expression of inflammation associated genes correlated with nociceptive responses. CONCLUSIONS: Protamine treatment of the bladder is analgesic and tissue protective, and it suppresses the inflammatory cytokine expression normally associated with nociception. Also, the injury modalities that result in differential tissue response patterns provide an innovative method for identifying mediators of visceral pain.
PURPOSE:Bladder pain is a debilitating symptom of many urological conditions. There is no generally effective treatment. Abnormal urothelial turnover is common to multiple disease states but the specific components of urothelial injury and the resulting molecular signals that lead to bladder pain are unknown. We examined mouse models of bladder injury induced by uropathogenic Escherichia coli, protamine sulfate (Sigma®) and bacterial lipopolysaccharide to identify cellular and molecular correlates underlying pain sensitization in response to the stimuli. MATERIALS AND METHODS: C57BL/6 female mice (Jackson Laboratory, Bar Harbor, Maine) were given intravesicular protamine sulfate, lipopolysaccharide or uropathogenic E. coli. The impact of each on nociception was determined by measuring the evoked visceromotor response to bladder distention 24 hours after inoculation. Levels of pyuria and tissue inflammation were examined by urinary cytology and tissue histology. Quantitative polymerase chain reaction and gene expression analysis were used to identify injury profiles associated with nociception. RESULTS: Protamine sulfate treatment was significantly analgesic upon bladder distention. Protamine treated bladders did not show pyuria or extensive tissue damage. Protamine injury was associated with a global decrease in the expression of inflammation associated genes. In contrast, uropathogenic E. coli injury significantly increased the nociceptive response to bladder distention. Lipopolysaccharide treatment did not affect nociception. Finally, injury induced expression of inflammation associated genes correlated with nociceptive responses. CONCLUSIONS: Protamine treatment of the bladder is analgesic and tissue protective, and it suppresses the inflammatory cytokine expression normally associated with nociception. Also, the injury modalities that result in differential tissue response patterns provide an innovative method for identifying mediators of visceral pain.
Authors: L A Birder; M Ruggieri; M Takeda; G van Koeveringe; S Veltkamp; C Korstanje; B Parsons; C H Fry Journal: Neurourol Urodyn Date: 2012-01-24 Impact factor: 2.696
Authors: D Porru; R Politanò; M Gerardini; G L Giliberto; S Stancati; L Pasini; C Tinelli; B Rovereto Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2004-02-05
Authors: Lara W Crock; Kristina M Stemler; David G Song; Philip Abbosh; Sherri K Vogt; Chang-Shen Qiu; H Henry Lai; Indira U Mysorekar; Robert W Gereau Journal: Mol Pain Date: 2012-03-26 Impact factor: 3.395
Authors: J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis Journal: Nat Rev Urol Date: 2019-03 Impact factor: 14.432
Authors: Patrick O Wagers; Kristin M Tiemann; Kerri L Shelton; William G Kofron; Matthew J Panzner; Karen L Wooley; Wiley J Youngs; David A Hunstad Journal: Antimicrob Agents Chemother Date: 2015-06-29 Impact factor: 5.191
Authors: Henry Lai; Robert W Gereau; Yi Luo; Michael O'Donnell; Charles N Rudick; Michel Pontari; Chris Mullins; David J Klumpp Journal: Urology Date: 2015-06 Impact factor: 2.649
Authors: Rheal A Towner; Nataliya Smith; Debra Saunders; Samuel B Van Gordon; Amy B Wisniewski; Karl R Tyler; Beverley Greenwood-Van Meerveld; Robert E Hurst Journal: J Urol Date: 2014-11-14 Impact factor: 7.450
Authors: Beverley Greenwood-Van Meerveld; Ehsan Mohammadi; Karl Tyler; Samuel Van Gordon; Alex Parker; Rheal Towner; Robert Hurst Journal: J Urol Date: 2015-03-14 Impact factor: 7.450
Authors: Kyle A Bauckman; Rina Matsuda; Cassandra B Higgins; Brian J DeBosch; Caihong Wang; Indira U Mysorekar Journal: Am J Physiol Renal Physiol Date: 2019-02-06
Authors: Nicholas S Gregory; Amber L Harris; Caleb R Robinson; Patrick M Dougherty; Perry N Fuchs; Kathleen A Sluka Journal: J Pain Date: 2013-09-12 Impact factor: 5.820
Authors: Christine C Yokoyama; Megan T Baldridge; Daisy W Leung; Guoyan Zhao; Chandni Desai; Ta-Chiang Liu; Vladimir E Diaz-Ochoa; Jeremy P Huynh; Jacqueline M Kimmey; Erica L Sennott; Camaron R Hole; Rachel A Idol; Sunmin Park; Kelly M Storek; Caihong Wang; Seungmin Hwang; Ashley Viehmann Milam; Eric Chen; Tobias Kerrinnes; Michael N Starnbach; Scott A Handley; Indira U Mysorekar; Paul M Allen; Denise M Monack; Mary C Dinauer; Tamara L Doering; Renee M Tsolis; Jonathan E Dworkin; Christina L Stallings; Gaya K Amarasinghe; Craig A Micchelli; Herbert W Virgin Journal: J Biol Chem Date: 2018-03-01 Impact factor: 5.157